Know Cancer

forgot password

Multicenter, Randomized Phase III Trial to Compare Epirubicin and Cyclophosphamide (EC) Followed by Docetaxel (T) to Epirubicin and Docetaxel (ET) Followed by Capecitabine (X) as Adjuvant Treatment for Operable, Node Positive Breast Cancer Patients

Phase 3
18 Years
70 Years
Not Enrolling
Breast Cancer

Thank you

Trial Information

Multicenter, Randomized Phase III Trial to Compare Epirubicin and Cyclophosphamide (EC) Followed by Docetaxel (T) to Epirubicin and Docetaxel (ET) Followed by Capecitabine (X) as Adjuvant Treatment for Operable, Node Positive Breast Cancer Patients

Inclusion Criteria:

- Written informed consent.

- Histological diagnosis of operable invasive adenocarcinoma of the breast (T1-T3).
Tumours must be HER2 negative. Time window between surgery and study randomization
must be less than 60 days.

- Surgery must consist of mastectomy or conservative surgery with axillary lymph node
dissection. Margins free of disease and ductal carcinomas in situ (DCIS) are
required. Lobular carcinoma is not considered a positive margin.

- Positive axillary lymph nodes defined as at least 1 out of 10 nodes with presence of
disease. If sentinel node technique is used, sentinel node can be the only node
affected. Patients belonging to the following classifications are eligible: pN1a,
pN2a, pN3a.

- Status of hormone receptors in primary tumour. Results must be available before the
end of adjuvant chemotherapy.

- Patients must not present evidence of metastatic disease. Status of HER2 in primary
tumour, known before randomization. Patients with immune histochemistry (IHC) 0 or +1
are eligible. For patients with ICH 2+, fluorescence in situ hybridization (FISH) is
mandatory and result must be negative.

- Age >= 18 and <= 70 years old.

- Performance status (Karnofsky index) >= 80.

- Normal electrocardiogram (EKG) in the 12 weeks prior to randomization. If needed,
normal cardiac function must be confirmed by left ventricular ejection fraction

- Laboratory results (within 14 days prior to randomization):

- Hematology: neutrophils >= 1.5 x 10^9/l; platelets >= 100 x 10^9/l; hemoglobin
>= 10 mg/dl;

- Hepatic function: total bilirubin <= 1 upper normal limit (UNL); SGOT and SGPT
<= 2.5 UNL; alkaline phosphatase <= 2.5 UNL. If values of SGOT and SGPT > 1.5
UNL are associated to alkaline phosphatase > 2.5 UNL, patient is not eligible;

- Renal function: creatinine <= 175 mmol/l (2 mg/dl); creatinine clearance >= 60

- Pharmacogenetics: one blood sample is needed for SNP assessment.

- Complete stage workup during the 12 weeks prior to randomization (mammograms are
allowed within a 20 week window). All patients must have a bilateral mammogram,
thorax x-ray, abdominal echography and/or computed tomography (CT)-scan. If bone
pain, and/or alkaline phosphatase elevation, a bone scintigraphy is mandatory. This
test is recommended for all patients. Other tests: as clinically indicated.

- Patients able to comply with treatment and study follow-up.

- Negative pregnancy test done in the 14 prior days to randomization.

Exclusion Criteria:

- Prior systemic therapy for breast cancer.

- Prior therapy with anthracyclines or taxanes (paclitaxel or docetaxel) for any

- Prior radiotherapy for breast cancer.

- Bilateral invasive breast cancer.

- Pregnant or lactating women. Adequate contraceptive methods must be used during
chemotherapy and hormone therapy treatments.

- Any T4 or M1 tumour.

- Axillary lymph nodes: patients belonging to the following classifications are
excluded: pN1b, pN1c, pN2b, pN3b, pN3c.

- HER2 positive breast cancer (IHC 3+ or positive FISH result).

- Pre-existing grade >= 2 motor or sensorial neurotoxicity (National Cancer Institute
Common Toxicity Criteria version 2.0 [NCI CTC v-2.0]).

- Any other serious medical pathology, such as congestive heart failure; unstable
angina; history of myocardial infarction during the previous year; uncontrolled HA or
high risk arrhythmias.

- History of neurological or psychiatric disorders, which could preclude the patients
from free informed consent.

- Active uncontrolled infection.

- Active peptic ulcer; unstable diabetes mellitus.

- Previous or current history of neoplasms different from breast cancer, except for
skin carcinoma, cervical in situ carcinoma, or any other tumour curatively treated
and without recurrence in the last 10 years; ductal in situ carcinoma in the same
breast; lobular in situ carcinoma.

- Chronic treatment with corticosteroids.

- Contraindications for corticosteroid administration.

- Concomitant treatment with raloxifene, tamoxifen or other selective estrogen receptor
modulators (SERMs), either for osteoporosis treatment or for prevention. These
treatments must stop before randomisation.

- Concomitant treatment with other investigational products; participation in other
clinical trials with a non-marketed drug in the 20 previous days before

- Concomitant treatment with another therapy for cancer.

- Males.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

5-year disease-free survival

Principal Investigator

Miguel Martín, MD., PhD.

Investigator Role:

Study Chair

Investigator Affiliation:

Spanish Breast Cancer Research Group (GEICAM)


Spain: Spanish Agency of Medicines

Study ID:

GEICAM 2003-10



Start Date:

February 2004

Completion Date:

February 2012

Related Keywords:

  • Breast Cancer
  • HER2 negative breast cancer
  • Node positive breast cancer
  • Adjuvant treatment
  • Oral chemotherapy
  • Breast Neoplasms